CVS BEATS EARNINGS BY $0.75 A SHARE AND THE STOCK FALLS 10.8%

🔴 CVS beat earnings by $0.75 a share. The stock is down 10.8% since.

Q2 2026 revenue landed at $106.1 billion, up 7.3% year on year and 6.7% ahead of consensus.

Adjusted net income came in at $2.58 per share. Analysts wanted $1.83.

It was not a one-off. Q1 delivered $2.57 against a $2.21 consensus, a $0.36 beat. Management raised full-year revenue and earnings guidance in both quarters.

📈 The driver was insurance, not the stores. Adjusted operating income in healthcare benefits rose 85% year on year to $2.4 billion in Q2, after a 52% jump to more than $3 billion in Q1. Reporting points to claims patterns and premium retention doing the heavy lifting.

CVS has also widened its work around weight-loss and obesity treatments, aimed at lifting prescription volumes while online and retail pharmacy competition stays intense and pharmacy wage costs need managing.

📉 The market is not buying it yet. Shares traded at $93.04 on August 24, with an intraday low of $92.54, after a 10.8% slide since the latest results. The average analyst price target stands at $114.59, roughly 22% above the recent close.

Google News — earnings shock reports the gap reflects caution over competitive dynamics and whether those margins hold.

Beats, raises, and a falling share price. Would you buy CVS at $93?

#CVS #earnings #stocks #healthcare #causeanuproar